Cargando…
One‐stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high‐risk foot
AIMS: To evaluate the feasibility of a one‐stop microvascular screening service for the early diagnosis of diabetic distal symmetrical polyneuropathy, painful distal symmetrical polyneuropathy and the at‐risk diabetic foot. METHODS: People with diabetes attending retinal screening in hospital and co...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033008/ https://www.ncbi.nlm.nih.gov/pubmed/29608799 http://dx.doi.org/10.1111/dme.13630 |
_version_ | 1783337616493510656 |
---|---|
author | Binns‐Hall, O. Selvarajah, D. Sanger, D. Walker, J. Scott, A. Tesfaye, S. |
author_facet | Binns‐Hall, O. Selvarajah, D. Sanger, D. Walker, J. Scott, A. Tesfaye, S. |
author_sort | Binns‐Hall, O. |
collection | PubMed |
description | AIMS: To evaluate the feasibility of a one‐stop microvascular screening service for the early diagnosis of diabetic distal symmetrical polyneuropathy, painful distal symmetrical polyneuropathy and the at‐risk diabetic foot. METHODS: People with diabetes attending retinal screening in hospital and community settings had their feet examined by a podiatrist. Assessment included: Toronto Clinical Neuropathy Score evaluation; a 10‐g monofilament test; and two validated, objective and quick measures of neuropathy obtained using the point‐of‐care devices ‘DPN‐Check’, a hand‐held device that measures sural nerve conduction velocity and amplitude, and ‘Sudoscan’, a device that measures sudomotor function. The diagnostic utility of these devices was assessed against the Toronto Clinical Neuropathy Score as the ‘gold standard’. RESULTS: A total of 236 consecutive people attending the retinal screening service, 18.9% of whom had never previously had their feet examined, were evaluated. The prevalence of distal symmetrical polyneuropathy, assessed using the Toronto Clinical Neuropathy Score, was 30.9%, and was underestimated by 10‐g monofilament test (14.4%). The prevalence of distal symmetrical polyneuropathy using DPN‐check was 51.5% (84.3% sensitivity, 68.3% specificity), 38.2% using Sudoscan foot electrochemical skin conductance (77.4% sensitivity, 68.3% specificity), and 61.9% using abnormality in either of the results (93.2% sensitivity, 52.8% specificity). The results of both devices correlated with Toronto Clinical Neuropathy Score (P<0.001). A new diagnosis of painful distal symmetrical polyneuropathy was made in 59 participants (25%), and 56.6% had moderate‐ or high‐risk foot. Participants rated the service very highly. CONCLUSIONS: Combined, eye, foot and renal screening is feasible, has a high uptake, reduces clinic visits, and identifies painful distal symmetrical polyneuropathy and the at‐risk foot. Combined large‐ and small‐nerve‐fibre assessment using non‐invasive, quantitative and quick point‐of‐care devices may be an effective model for the early diagnosis of distal symmetrical polyneuropathy. |
format | Online Article Text |
id | pubmed-6033008 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-60330082018-07-12 One‐stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high‐risk foot Binns‐Hall, O. Selvarajah, D. Sanger, D. Walker, J. Scott, A. Tesfaye, S. Diabet Med Research Articles AIMS: To evaluate the feasibility of a one‐stop microvascular screening service for the early diagnosis of diabetic distal symmetrical polyneuropathy, painful distal symmetrical polyneuropathy and the at‐risk diabetic foot. METHODS: People with diabetes attending retinal screening in hospital and community settings had their feet examined by a podiatrist. Assessment included: Toronto Clinical Neuropathy Score evaluation; a 10‐g monofilament test; and two validated, objective and quick measures of neuropathy obtained using the point‐of‐care devices ‘DPN‐Check’, a hand‐held device that measures sural nerve conduction velocity and amplitude, and ‘Sudoscan’, a device that measures sudomotor function. The diagnostic utility of these devices was assessed against the Toronto Clinical Neuropathy Score as the ‘gold standard’. RESULTS: A total of 236 consecutive people attending the retinal screening service, 18.9% of whom had never previously had their feet examined, were evaluated. The prevalence of distal symmetrical polyneuropathy, assessed using the Toronto Clinical Neuropathy Score, was 30.9%, and was underestimated by 10‐g monofilament test (14.4%). The prevalence of distal symmetrical polyneuropathy using DPN‐check was 51.5% (84.3% sensitivity, 68.3% specificity), 38.2% using Sudoscan foot electrochemical skin conductance (77.4% sensitivity, 68.3% specificity), and 61.9% using abnormality in either of the results (93.2% sensitivity, 52.8% specificity). The results of both devices correlated with Toronto Clinical Neuropathy Score (P<0.001). A new diagnosis of painful distal symmetrical polyneuropathy was made in 59 participants (25%), and 56.6% had moderate‐ or high‐risk foot. Participants rated the service very highly. CONCLUSIONS: Combined, eye, foot and renal screening is feasible, has a high uptake, reduces clinic visits, and identifies painful distal symmetrical polyneuropathy and the at‐risk foot. Combined large‐ and small‐nerve‐fibre assessment using non‐invasive, quantitative and quick point‐of‐care devices may be an effective model for the early diagnosis of distal symmetrical polyneuropathy. John Wiley and Sons Inc. 2018-05-10 2018-07 /pmc/articles/PMC6033008/ /pubmed/29608799 http://dx.doi.org/10.1111/dme.13630 Text en © 2018 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Articles Binns‐Hall, O. Selvarajah, D. Sanger, D. Walker, J. Scott, A. Tesfaye, S. One‐stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high‐risk foot |
title | One‐stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high‐risk foot |
title_full | One‐stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high‐risk foot |
title_fullStr | One‐stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high‐risk foot |
title_full_unstemmed | One‐stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high‐risk foot |
title_short | One‐stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high‐risk foot |
title_sort | one‐stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high‐risk foot |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033008/ https://www.ncbi.nlm.nih.gov/pubmed/29608799 http://dx.doi.org/10.1111/dme.13630 |
work_keys_str_mv | AT binnshallo onestopmicrovascularscreeningserviceaneffectivemodelfortheearlydetectionofdiabeticperipheralneuropathyandthehighriskfoot AT selvarajahd onestopmicrovascularscreeningserviceaneffectivemodelfortheearlydetectionofdiabeticperipheralneuropathyandthehighriskfoot AT sangerd onestopmicrovascularscreeningserviceaneffectivemodelfortheearlydetectionofdiabeticperipheralneuropathyandthehighriskfoot AT walkerj onestopmicrovascularscreeningserviceaneffectivemodelfortheearlydetectionofdiabeticperipheralneuropathyandthehighriskfoot AT scotta onestopmicrovascularscreeningserviceaneffectivemodelfortheearlydetectionofdiabeticperipheralneuropathyandthehighriskfoot AT tesfayes onestopmicrovascularscreeningserviceaneffectivemodelfortheearlydetectionofdiabeticperipheralneuropathyandthehighriskfoot |